Holen Sie sich die Stockscreener-App
51.65
1.69%
0.86
Handel nachbörslich:
51.25
-0.40
-0.77%
Schlusskurs vom Vortag:
$50.79
Offen:
$50.62
24-Stunden-Volumen:
2.73M
Relative Volume:
0.82
Marktkapitalisierung:
$22.90B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$1.32B
KGV:
29.01
EPS:
1.7806
Netto-Cashflow:
$897.24M
1W Leistung:
+2.89%
1M Leistung:
+7.83%
6M Leistung:
+32.57%
1J Leistung:
+55.81%
1-Tages-Spanne:
$50.48
$51.72
1-Wochen-Bereich:
$49.28
$51.72
52-Wochen-Spanne:
$32.15
$51.72
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
51.65 | 22.51B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
435.17 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
712.77 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
813.28 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
284.84 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
310.75 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Income Investors Should Know That Royalty Pharma plc (NASDAQ:RPRX) Goes Ex-Dividend Soon - Yahoo Finance
Hosking Partners LLP Purchases 155,450 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
C WorldWide Group Holding A S Has $27.07 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Accelerated Royalty Deals and Dividend Hike Could Be A Game Changer For Royalty Pharma (RPRX) - simplywall.st
MSN Money - MSN
Royalty Pharma (NASDAQ:RPRX) Upgraded at Wall Street Zen - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
Christopher Hite gains 24,263 Royalty Pharma (RPRX) shares via equity award - Stock Titan
Royalty Pharma (RPRX) EVP gets 18,197-share equity award - Stock Titan
10% Of This Royalty Pharma Insider's Holdings Were Sold - Yahoo Finance
Royalty Pharma raises 2026 portfolio receipts guidance to $3.325B-$3.45B as it scales R&D co-funding - MSN
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Citigroup Raises Royalty Pharma (NASDAQ:RPRX) Price Target to $66.00 - MarketBeat
Royalty Pharma schedules two May healthcare conference webcasts - Stock Titan
JPMorgan Chase & Co. Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Denali Therapeutics (NASDAQ: DNLI) adds cash on AVLAYAH deal despite Q1 loss - Stock Titan
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
Theravance Biopharma (NASDAQ: TBPH) slashes R&D after ampreloxetine trial miss - Stock Titan
Vanguard Group Inc. Cuts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Q1 2026 Earnings Call Transcript - Insider Monkey
Royalty Pharma Q1 2026 slides: double-digit growth, guidance raised By Investing.com - Investing.com Australia
Royalty Pharma Earnings: Strong Cash Flows and New Deals Support Positive Outlook and Key Readouts - Morningstar
Royalty Pharma (RPRX) Margin Drop To 33.9% Tests Bullish Growth Narrative In Q1 2026 - Sahm
Improved Growth Outlook Prompts Fair Value Estimate Increase for Narrow-Moat Royalty Pharma - Morningstar
Royalty Pharma’s Earnings Call Signals Confident Growth - TipRanks
Royalty Pharma Q1 Earnings Call Highlights - MarketBeat
Royalty Pharma plc Q1 2026 Financial Results: Earnings, Revenue, and Risk Factors from Latest 10-Q Filing - Minichart
Royalty Pharma Q1 2026 earnings preview - MSN
Royalty Pharma plc Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Royalty Pharma Q1 2026 shows robust growth By Investing.com - Investing.com India
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript - AOL.com
Royalty Pharma Reports 10% Growth in Portfolio Receipts for Q1 2026 Driven by Strong Product Performance - Minichart
RPRX vs. AMGN: Which Stock Is the Better Value Option? - Yahoo! Finance Canada
Royalty Pharma Q1 2026 slides: double-digit growth, guidance raised - Investing.com
Royalty Pharma PLC reports results for the quarter ended March 31Earnings Summary - TradingView
Royalty Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Royalty Pharma (RPRX) Valuation Check As Q1 Earnings Expectations Drive Strong Share Price Momentum - Sahm
RPRX Stock Price Prediction 2025-2026 | Royalty Pharma Plc Forecast | 24/7 Wall St. - 24/7 Wall St.
Earnings call transcript: Royalty Pharma Q1 2026 shows robust growth - Investing.com
Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Royalty Pharma plc 1Q 2026: Revenue $630.58M, EPS $0.67— 10-Q Summary - TradingView
Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on January 10, 2025. - marketscreener.com
Royalty Pharma (NASDAQ: RPRX) grows Q1 2026 profit and cash flow - Stock Titan
Royalty Pharma plc 2026 Q1ResultsEarnings Call Presentation (NASDAQ:RPRX) 2026-05-06 - Seeking Alpha
Earnings Flash (RPRX) Royalty Pharma plc Reports Q1 Revenue $631.0M - marketscreener.com
Royalty Pharma : Q1 2026 Financial Results Presentation - marketscreener.com
Royalty Pharma posts Q1 2026 Portfolio Receipts $925M; raises 2026 guidance to $3.325B‑$3.45B - TradingView
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.51%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):